Our host speaks with Assoc Prof Jimmy Teo, Senior Consultant nephrologist from National University Hospital Singapore and Dr Tan Li Ping, Consultant Nephrologist from Ara Damansara Medical Centre Malaysia, to discuss the baseline characteristics of EMPA-Kidney trial, the latest study in SGLT2 inhibitor and CKD.
Note: Empagliflozin is not indicated for the treatment of chronic kidney disease.